Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6)

European Journal of Medicinal Chemistry

Volumn 138, Issue , 2017, Pages 661-668

  Cingolani, Gino ^a,b   Panella, Andrea ^c   Perrone, Maria Grazia ^c   Vitale, Paola ^c   Di Mauro, Giuseppe ^d   Fortuna, Cosimo G ^d   Armen, Roger S ^e   Ferorelli, Savina ^c   Smith, William L ^f   Scilimati, Antonio ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CNR   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cyclooxygenase 1 inhibition; Diarylisoxazole; Mofezolac; Molecular modelling; P6; X ray crystallography

Indexed keywords

3 (5 CHLOROFURAN 2 YL) 5 METHYL 4 PHENYLISOXAZOLE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; ISOXAZOLE DERIVATIVE; MOFEZOLAC; UNCLASSIFIED DRUG; 3-(5-CHLOROFURAN-2-YL)-5-METHYL-4-PHENYLISOXAZOLE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; SYNTHESIS;

CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOXAZOLES; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85022319489     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2017.06.045     Document Type: Article

References (40)

1. Smith, W.L., Garavito, R.M., DeWitt, D.L., Prostaglandin endoperoxide H synthases (cyclooxygenases) -1 and -2. J. Biol. Chem. 271 (1996), 33157–33160.
2. Marnett, L.J., Rowlinson, S.W., Goodwin, D.C., Kalgurtkar, A.S., Lanzo, C.A., Arachidonic acid oxygenation by COX-1 and COX-2 – mechanism of catalysis and inhibition. J. Biol. Chem. 274 (1999), 22903–22906.
3. Smith, W.L., DeWitt, D.L., Garavito, R.M., Cyclooxygenase: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000), 149–182.
4. Perrone, M.G., Scilimati, A., Simone, L., Vitale, P., Selective COX-1 inhibition: a therapeutic target to be reconsidered. Curr. Med. Chem. 17 (2010), 3769–3805.
5. Vitale, P., Scilimati, A., Perrone, M.G., Update on SAR studies toward new COX-1 selective inhibitors. Curr. Med. Chem. 22 (2015), 4271–4292.
6. Vane, J.R., Botting, R.M., The mechanism of action of aspirin. Thromb. Res. 110 (2003), 255–258.
7. Di Nunno, L., Vitale, P., Scilimati, A., Tacconelli, S., Patrignani, P., Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J. Med. Chem. 47 (2004), 4881–4890.
8. Vitale, P., Tacconelli, S., Perrone, M.G., Malerba, P., Simone, L., Scilimati, A., Lavecchia, A., Dovizio, M., Marcantoni, E., Bruno, A., Patrignani, P., Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. J. Med. Chem. 56 (2013), 4277–4299.
9. Uddin, M.J., Elleman, A.V., Ghebreselasie, K., Daniel, C.K., Crews, B.C., Nance, K.D., Huda, T., Marnett, L.J., Design of fluorine-containing 3,4-diarylfuran-2(5H)-ones as selective COX-1 inhibitors. ACS Med. Chem. Lett. 5 (2014), 1254–1258.
10. Perrone, M.G., Vitale, P., Panella, A., Scilimati, A., COX-1 inhibitors: beyond structure towards therapy. Med. Rev. Res. 36 (2016), 641–671.
11. Perrone, M.G., Lofrumento, D.D., Vitale, P., De Nuccio, F., La Pesa, V., Panella, A., Calvello, R., Cianciulli, A., Panaro, M.A., Scilimati, A., Selective cyclooxygenase-1 inhibition by P6 and gastrotoxicity: preliminary investigation. Pharmacol 95 (2015), 22–28.
12. Kakuta, H., Zheng, X., Oda, H., Harada, S., Sugimoto, Y., Sasaki, K., Tai, A., Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. J. Med. Chem. 51 (2008), 2400–2411.
13. Kakuta, H., Fukai, R., Xiaoxia, Z., Ohsawa, F., Bamba, T., Hirata, K., Tai, A., Identification of urine metabolites of TFAP, a cyclooxygenase-1 inhibitor. Bioorg. Med. Chem. Lett. 20 (2010), 840–843.
14. Perrone, M.G., Vitale, P., Panella, P., Fortuna, C.G., Scilimati, A., General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model. Eur. J. Med. Chem. 94 (2015), 252–264.
15. Vitale, P., Perrone, M.G., Malerba, P., Lavecchia, A., Scilimati, A., Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles. Eur. J. Med. Chem. 74 (2014), 1–13.
16. Perrone, M.G., Vitale, P., Panella, A., Ferorelli, S., Contino, M., Lavecchia, A., Scilimati, A., Isoxazole-based scaffold inhibitors targeting cyclooxygenase(COX)s. Chem. Med. Chem. 11 (2016), 1172–1187.
17. Picot, D., Loll, P.J., Garavito, R.M., The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367 (1994), 243–249.
18. Mancini, J.A., Riendeau, D., Falgueyret, J.P., Vickers, P.J., O'Neill, G.P., Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J. Biol. Chem. 270 (1995), 29372–29377.
19. Goto, K., Ochi, H., Yasunaga, Y., Matsuyuki, H., Imayoshi, T., Kusuhara, H., Okumoto, T., Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice - a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostagl. Other Lipid Mediat. 56 (1998), 245–254.
20. Kitamura, T., Kawamori, T., Uchiya, N., Itoh, M., Noda, T., Matsuura, M., Sugimura, T., Wakabayashi, K., Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis 23 (2002), 1463–1466.
21. Calvello, R., Lofrumento, D.D., Perrone, M.G., Cianciulli, A., Salvatore, R., Vitale, P., De Nuccio, F., Giannotti, L., Nicolardi, G., Panaro, M.A., Scilimati, A., Highly Selective Cyclooxygenase-1 Inhibitors P6 and Mofezolac Counteract Inflammatory State both In Vitro and In Vivo Models of Neuroinflammation. Front. Neurol. 8 (2017), 1–10 Article 251.
22. Sidhu, R.S., Lee, J.Y., Yuan, C., Smith, W.L., Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers. Biochemistry 49 (2010), 7069–7079.
23. Gupta, K., Selinsky, B.S., Kaub, C.J., Katz, A.K., Loll, P.J., The 2.0 A resolution crystal structure of prostaglandin H2 synthase-1: structural insights into an unusual peroxidase. J. Mol. Biol. 335 (2004), 503–518.
24. Xu, S., Hermanson, D.J., Banerjee, S., Ghebreselasie, K., Clayton, G.M., Garavito, R.M., Marnett, L.J., Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding network. J. Biol. Chem. 289 (2014), 6799–6808.
25. Sankhala, S.R., Lokareddy, K.R., Cingolani, G., Structure of human PIR1, an atypical dual specificity phosphatase. Biochemistry 53 (2014), 862–871.
26. Khan, Y.S., Kazemi, M., Gutiérrez-de-Terán, H., Åqvist, J., Origin of the enigmatic stepwise tight-binding inhibition of cyclooxygenase-1. Biochemistry 54 (2015), 7283–7291.
27. Grosser, T., Fries, S., FitzGerald, G.A., Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest 116 (2006), 4–15.
28. Luong, C., Miller, A., Barnett, J., Chow, J., Ramesha, C., Browner, M.F., Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol 3 (1996), 927–933.
29. Baroni, M., Cruciani, G., Sciabola, S., Perruccio, F., Mason, J.S., A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for ligands and proteins (FLAP): theory and application. J. Chem. Inf. Model 47 (2007), 279–294.
30. Perrone, M.G., Malerba, P., Uddin, Md. J., Vitale, P., Panella, A., Crews, B.C., Daniel, C.K., Ghebreselasie, K., Nickels, M., Tantawy, M.N., Manning, H.C., Marnett, L.J., Scilimati, A., PET radiotracer [18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: Preliminary investigation. Eur. J. Med. Chem. 80 (2014), 562–568.
31. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit. Med. J. 324 (2002), 71–86.
32. Patrignani, P., Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb. Res. 110 (2003), 281–286.
33. R.G. Micetich, C.C. Shaw, R.B. Rastogi, Eur Patent 26928 (1981).
34. Otwinowski, Z., Minor, W., Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997), 307–326 Macromolecular Crystallography (part A, C.W. Carter, Jr. & R.M. Sweet, Eds., Academic Press).
35. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J., Phaser crystallographic software. J. Appl. Crystallogr. 40 (2007), 658–674.
36. Adams, P.D., Grosse-Kunstleve, R.W., Hung, L.W., Ioerger, T.R., McCoy, A.J., Moriarty, N.W., Read, R.J., Sacchettini, J.C., Sauter, N.K., Terwilliger, T.C., PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D. Biol. Crystallogr. 58 (2002), 1948–1954.
37. Liebschner, D., Afonine, P.V., Moriarty, N.W., Poon, B.K., Sobolev, O.V., Terwilliger, T.C., Adams, P.D., Polder maps: improving OMIT maps by excluding bulk solvent. Acta Crystallogr. D Struct. Biol. 73 (2017), 148–157.
38. Emsley, P., Coot, C.K., Model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60 (2004), 2126–2132.
39. DeLano, W.L., The PyMOL Molecular Graphics System. 2002, World Wide Web http://www.pymol.org.
40. Rahaman, O., Estrada, T.P., Doren, D.J., Taufer, M., Brooks, C.L. 3rd, Armen, R.S., Evaluation of several two-step scoring functions based on linear interaction energy, effective ligand size, and empirical pair potentials for prediction of protein-ligand binding geometry and free energy. J. Chem. Inf. Model 51 (2011), 2047–2065.